# Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease

> **NCT05049525** · PHASE2 · TERMINATED · sponsor: **Montreal Heart Institute** · enrollment: 16 (actual)

## Conditions studied

- Crohn's Disease
- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.
- **DRUG:** Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.

## Key facts

- **NCT ID:** NCT05049525
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-22
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Insufficient patient enrollment
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049525, "Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05049525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*